IntegraGen today announced that it has successfully completed a capital increase with cancellation of preferential subscription rights, reserved for a category of investors in the amount of € 3.7 million.

Objectives of Fundraising

The funds received will permit IntegraGen to accelerate its development by supporting the deployment of the following new activities:

  • Launch of kit production miRpredX: commercialization of a predictive diagnostic kit for response to anti-EGFR treatment for patients with metastatic colorectal cancer.
  • Development of ICE (Interpretation of Clinical Exome), a software tool for interpreting clinical genomics data in cancer patients

The funds will also enable IntegraGen’s genomic services platforms to be strengthened with newer technologies.


Click here to view press release